175965-65-8

Basic information

• Product Name: 8-METHOXY-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE
• Synonyms: 8-METHOXY-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE;8-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine;8-Methoxy-[1,2,4]triazol[1,5-a]pyridine-2-amine
• CAS NO: 175965-65-8
• Molecular Formula: C₇H₈N₄O
• Molecular Weight: 164.16
• Mol File: 175965-65-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.48
• Refractive Index: 1.701
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 8-METHOXY-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-METHOXY-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE(175965-65-8)
• EPA Substance Registry System: 8-METHOXY-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE(175965-65-8)

Safety Data

• Hazardous Substances Data: 175965-65-8(Hazardous Substances Data)

Usage

General Description

8-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine is a chemical compound with the molecular formula C8H8N4O. It is a derivative of pyridine and triazole, and its structure includes a triazole ring fused to a pyridine ring, with a methoxy group and an amine group attached at specific positions. 8-METHOXY-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE may have potential applications in medicinal chemistry and drug discovery due to its unique structure and potential biological activities. Further research is needed to fully understand the properties and potential uses of 8-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-amine.

InChI:InChI=1/C7H8N4O/c1-12-5-3-2-4-11-6(5)9-7(8)10-11/h2-4H,1H3,(H2,8,10)

Upstream product

• 20265-37-6 3-methoxy-2-nitropyridine 
• 10201-71-5 3-methoxypyridin-2-amine 
• 16182-04-0 Ethoxycarbonyl isothiocyanate 
• 175965-58-9 ethyl N-[(3-methoxypyridin-2-yl)carbamothioyl]carbamate 

Downstream Products

• 492468-97-0 8-methoxy-5-iodo-[1,2,4]triazolo[1,5-a]pyridin-2-yl-amine 
• 1319064-55-5 5-(8-Methoxy-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile 
• 634195-36-1 8-methoxy-5-(4-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine 
• 634195-42-9 8-methoxy-5-(3-trifluoromethyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine 
• 685135-47-1 8-methoxy-5-o-tolyl-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine 
• 492468-98-1 8-methoxy-5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-amine 
• 1319067-40-7 2-bromo-8-methoxy-[1,2,4]triazolo[1,5-a]pyridine 

Relevant articles and documents

Stepwise Design of γ-Secretase Modulators with an Advanced Profile by Judicious Coordinated Structural Replacements and an Unconventional Phenyl Ring Bioisostere

Starting from RO6800020 (1), our former γ-secretase modulator (GSM) lead compound, we utilized sequential structural replacements to improve the potency (IC50), pharmacokinetic properties including the free fraction (fraction unbound (fu)) in plasma, and in vivo efficacy. Importantly, we used novel CF3-alkoxy groups as bioisosteric replacements of a fluorinated phenyl ring and properties such as lipophilicity, solubility, metabolic stability, and free fraction could be balanced, maintaining low Pgp efflux needed for CNS penetration. In addition, by reducing aromaticity, we prevented phototoxicity. Additional substitution in the triazolopyridine core disturbed the binding to phosphatidylinositol 4-kinase, catalytic β (PIK4CB). We also introduced less lipophilic head heterocycles devoid of covalent binding (CVB) liability. After these changes, further modifications to the trifluoroethoxy bioisosteric replacement allowed rebalancing of properties, such as lipophilicity, and also potency. Our optimization strategy culminated with in vivo active RO7101556 (18B) having excellent properties and being selected as an advanced candidate.

BRIDGED PIPERIDINE DERIVATIVES

The present invention relates to a compound of formula (I), wherein Het Ar is a five or six membered hetaryl group, containing one, two or three heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, lower alkyl substituted by halogen, halogen, or lower alkoxy; R2 is lower alkyl substituted by halogen, -CH2-C3-6-cycloalkyl, substituted by one or two substituents, selected from lower alkyl substituted by halogen or halogen, or is lower alkenyl substituted by halogen; R3 is hydrogen, lower alkyl substituted by halogen, lower alkyl, halogen, C3-6-cycloalkyl or lower alkyl substituted by hydroxy; n is 1 or 2; for n = 2, R1 can be independent to each other; Y is CH or N; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives

The invention is a compound of formula or a pharmaceutically acceptable salt thereof, wherein R1and R2are as defined in the specification. A compound of formula I has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor.